OncoSec Medical Inc. has entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec’s ImmuoPulse IL-12 with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in a phase II clinical trial, referred to as PISCES.
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
